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Summary
Background In an era of shifting global agendas and expanded emphasis on non-communicable diseases and injuries 
along with communicable diseases, sound evidence on trends by cause at the national level is essential. The Global 
Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic scientific assessment of published, 
publicly available, and contributed data on incidence, prevalence, and mortality for a mutually exclusive and 
collectively exhaustive list of diseases and injuries.
Methods GBD estimates incidence, prevalence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and 
disability-adjusted life-years (DALYs) due to 369 diseases and injuries, for two sexes, and for 204 countries and territories. 
Input data were extracted from censuses, household surveys, civil registration and vital statistics, disease registries, 
health service use, air pollution monitors, satellite imaging, disease notifications, and other sources. Cause-specific 
death rates and cause fractions were calculated using the Cause of Death Ensemble model and spatiotemporal Gaussian 
process regression. Cause-specific deaths were adjusted to match the total all-cause deaths calculated as part of the GBD 
population, fertility, and mortality estimates. Deaths were multiplied by standard life expectancy at each age to calculate 
YLLs. A Bayesian meta-regression modelling tool, DisMod-MR 2.1, was used to ensure consistency between incidence, 
prevalence, remission, excess mortality, and cause-specific mortality for most causes. Prevalence estimates were 
multiplied by disability weights for mutually exclusive sequelae of diseases and injuries to calculate YLDs. We considered 
results in the context of the Socio-demographic Index (SDI), a composite indicator of income per capita, years of 
schooling, and fertility rate in females younger than 25 years. Uncertainty intervals (UIs) were generated for every 
metric using the 25th and 975th ordered 1000 draw values of the posterior distribution.
Findings Global health has steadily improved over the past 30 years as measured by age-standardised DALY rates. After 
taking into account population growth and ageing, the absolute number of DALYs has remained stable. Since 2010, the 
pace of decline in global age-standardised DALY rates has accelerated in age groups younger than 50 years compared 
with the 1990–2010 time period, with the greatest annualised rate of decline occurring in the 0–9-year age group. 
Six infectious diseases were among the top ten causes of DALYs in children younger than 10 years in 2019: lower 
respiratory infections (ranked second), diarrhoeal diseases (third), malaria (fifth), meningitis (sixth), whooping cough 
(ninth), and sexually transmitted infections (which, in this age group, is fully accounted for by congenital syphilis; ranked 
tenth). In adolescents aged 10–24 years, three injury causes were among the top causes of DALYs: road injuries (ranked 
first), self-harm (third), and interpersonal violence (fifth). Five of the causes that were in the top ten for ages 10–24 years 
were also in the top ten in the 25–49-year age group: road injuries (ranked first), HIV/AIDS (second), low back pain 
(fourth), headache disorders (fifth), and depressive disorders (sixth). In 2019, ischaemic heart disease and stroke were the 
top-ranked causes of DALYs in both the 50–74-year and 75-years-and-older age groups. Since 1990, there has been a 
marked shift towards a greater proportion of burden due to YLDs from non-communicable diseases and injuries. 
In 2019, there were 11 countries where non-communicable disease and injury YLDs constituted more than half of all 
disease burden. Decreases in age-standardised DALY rates have accelerated over the past decade in countries at the lower 
end of the SDI range, while improvements have started to stagnate or even reverse in countries with higher SDI.
Interpretation As disability becomes an increasingly large component of disease burden and a larger component of 
health expenditure, greater research and development investment is needed to identify new, more effective 
intervention strategies. With a rapidly ageing global population, the demands on health services to deal with 
disabling outcomes, which increase with age, will require policy makers to anticipate these changes. The mix of 
universal and more geographically specific influences on health reinforces the need for regular reporting on 
population health in detail and by underlying cause to help decision makers to identify success stories of disease 
control to emulate, as well as opportunities to improve.
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Introduction
The Global Burden of Diseases, Injuries, and Risk Factors 
Study (GBD) provides a systematic scientific assess ment 
of published, publicly available, and contributed data on 
disease and injury incidence, prevalence, and mortality 
for a mutually exclusive and collectively exhaustive list 
of diseases and injuries.1–3 In an era of shifting global 
agendas and expanded emphasis on non-communicable 
diseases and injuries along with communicable diseases, 
sound and up-to-date evidence on trends—both progress 
and adverse patterns—by cause at the national level is 
essential to reflect effects of public health policy and 
medical care delivery.4–7
GBD 2019 provides an opportunity to incorporate 
newly available datasets, enhance method performance 
and standardisation, and reflect changes in scientific 
understanding. Since GBD 2017,1–3 no comprehensive 
update of descriptive epidemiology levels and trends has 
been released, to our knowledge. In this study, we 
summarise GBD methods and present integrated results 
on fatal and non-fatal outcomes for the GBD disease 
and injury hierarchical cause list. GBD 2019 includes 
estimation of numerous different models for disease and 
injury outcomes. This Article provides a high-level over-
view of our findings. Results are presented both broadly 
and in detail for a selection of diseases, injuries, and 
impairments in two-page summaries with a standard set 
of tables and figures.
Methods
Overview
The general approach to estimating causes of death and 
disease incidence and prevalence for GBD 2019 is the 
same as for GBD 2017.2,3 Appendix 1 provides details on 
the methods used to model each disease and injury. 
Here, we provide an overview of the methods, with an 
Research in context
Evidence before this study
The Global Burden of Diseases, Injuries, and Risk Factors Study 
(GBD) 2017 reported on incidence, prevalence, and mortality 
from 359 diseases and injuries. Information on prevalence and 
mortality was also analysed in terms of summary measures: 
years of life lost (YLLs), years lived with disability (YLDs), 
disability-adjusted life-years (DALYs), and healthy life 
expectancy. GBD is the only comprehensive assessment 
providing time trends for a mutually exclusive and collectively 
exhaustive list of diseases and injuries. For the first time, 
GBD 2017 also produced internally consistent estimates of 
population, fertility, mortality, and migration by age, sex, 
and year for 1950–2017. GBD 2017 also included subnational 
assessments for 16 countries at administrative level 1 and for 
local authorities in England.
Added value of this study
GBD 2019 updates and expands beyond GBD 2017 in ten ways. 
(1) The number of countries for which subnational assessments 
have been undertaken was expanded to include Italy, Nigeria, 
Pakistan, the Philippines, and Poland. (2) 12 new causes were 
added to the GBD modelling framework, including pulmonary 
arterial hypertension, nine new sites of cancer, and two new 
sites of osteoarthritis (hand and other joints). (3) For each 
disease, the preferred or reference case definition or 
measurement method was clearly defined and stored in a 
database. For both risks and diseases, the statistical relationship 
between the alternative and reference measurement method 
was analysed using network meta-regression using only data 
where two different approaches were measured in the same 
location–time period. Although statistical cross-walking 
between alternative and reference definitions and 
measurement methods has been a feature in all GBD studies, 
the approach in GBD 2019 was highly standardised and used 
improved methods across diseases and risks. (4) Some prior 
distributions used in DisMod-MR, the Bayesian meta-regression 
tool used to simultaneously estimate incidence, prevalence, 
remission, excess mortality, and cause-specific mortality, 
were revised on the basis of simulation studies showing that 
less informative priors helped to improve the coverage of 
uncertainty intervals. (5) Redistribution algorithms for sepsis, 
heart failure, pulmonary embolism, acute kidney injury, hepatic 
failure, acute respiratory failure, pneumonitis, and five 
intermediate causes in the central nervous system were revised 
according to an analysis of 116 million deaths that were 
attributed to multiple causes. (6) Processing of clinical 
informatics data on hospital and clinic visits was revised to 
better take into account differential access across locations to 
health-care facilities. (7) To enhance the stability of models in 
the presence of the addition of subnational data in different 
GBD cycles, we adopted a set of standard locations for the 
estimation of covariate effects in models. (8) 7333 national and 
24 657 subnational vital registration systems, 16 984 published 
studies, and 1654 household surveys were used in the analysis, 
including many newly available data sources. (9) Results are 
presented so as to integrate causes of death, incidence, 
prevalence, YLDs, YLLs, and DALYs into a comprehensive 
assessment of each disease and injury. (10) Closer technical 
coordination with WHO has led to the addition of nine WHO 
member states to the analysis and revisions of the analytical 
approach for select diseases.
Implications of all the available evidence
GBD 2019 provides the most up-to-date assessment of the 
descriptive epidemiology of a mutually exclusive and collectively 
exhaustive list of diseases and injuries for 204 countries and 
territories from 1990 to 2019. The comprehensive nature of the 
assessment provides policy-relevant information on the trends 
of major causes of burden globally, regionally, and by country or 
territory.
See Online for appendix 1
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emphasis on the main methodology changes since 
GBD 2017.
For each iteration of GBD, the estimates for the whole 
time series are updated on the basis of addition of new 
data and change in methods where appropriate. Thus, 
the GBD 2019 results supersede those from previous 
rounds of GBD.
GBD 2019 complies with the Guidelines for Accurate 
and Transparent Health Estimates Reporting (GATHER) 
statement (appendix 1 section 1.4).8 Analyses were com-
pleted with Python version 3.6.2, Stata version 13, and 
R version 3.5.0. Statistical code used for GBD estimation 
is publicly available online.
Geographical units, age groups, time periods, and cause 
levels
GBD 2019 estimated each epidemiological quantity of 
interest—incidence, prevalence, mortality, years lived 
with disability (YLDs), years of life lost (YLLs), and 
disability-adjusted life-years (DALYs)—for 23 age 
groups; males, females, and both sexes combined; and 
204 countries and territories that were grouped into 
21 regions and seven super-regions. For GBD 2019, 
nine countries and territories (Cook Islands, Monaco, 
San Marino, Nauru, Niue, Palau, Saint Kitts and Nevis, 
Tokelau, and Tuvalu) were added, such that the GBD 
location hierarchy now includes all WHO member 
states. GBD 2019 includes subnational analyses for 
Italy, Nigeria, Pakistan, the Philippines, and Poland, 
and 16 countries previously estimated at subnational 
levels (Brazil, China, Ethiopia, India, Indonesia, Iran, 
Japan, Kenya, Mexico, New Zealand, Norway, Russia, 
South Africa, Sweden, the UK, and the USA). All 
subnational analyses are at the first level of admin-
istrative organisation within each country except for 
New Zealand (by Māori ethnicity), Sweden (by 
Stockholm and non-Stockholm), the UK (by local gov-
ernment authorities), and the Philippines (by province). 
In this publication, we present subnational estimates 
for Brazil, India, Indonesia, Japan, Kenya, Mexico, 
Sweden, the UK, and the USA; given space constraints, 
these results are presented in appendix 2. At the most 
detailed spatial resolution, we generated estimates for 
990 locations. The GBD diseases and injuries analytical 
framework generated estimates for every year from 
1990 to 2019.
Diseases and injuries were organised into a levelled 
cause hierarchy from the three broadest causes of death 
and disability at Level 1 to the most specific causes at 
Level 4. Within the three Level 1 causes—communicable, 
maternal, neonatal, and nutritional diseases; non-com mu-
nicable diseases; and injuries—there are 22 Level 2 causes, 
174 Level 3 causes, and 301 Level 4 causes (including 
131 Level 3 causes that are not further disaggregated at 
Level 4; see appendix 1 sections 3.4 and 4.12 for the full list 
of causes). 364 total causes are non-fatal and 286 are fatal. 
For GBD 2019, 12 new causes were added to the modelling 
framework: pulmonary arterial hypertension, eye cancer, 
soft tissue and other extraosseous sarcomas, malignant 
neoplasm of bone and articular cartilage, and neuro-
blastoma and other peripheral nervous cell tumours at 
Level 3, and hepatoblastoma, Burkitt lymphoma, other 
non-Hodgkin lymphoma, retinoblastoma, other eye can-
cers, and two sites of osteoarthritis (hand and other joints) 
at Level 4.
Data
The GBD estimation process is based on identifying 
multiple relevant data sources for each disease or injury 
including censuses, household surveys, civil registration 
and vital statistics, disease registries, health service use, 
air pollution monitors, satellite imaging, disease notifi-
cations, and other sources. Each of these types of data are 
identified from systematic review of published studies, 
searches of government and international organisation 
websites, published reports, primary data sources such as 
the Demographic and Health Surveys, and contributions 
of datasets by GBD collaborators. 86 249 sources were 
used in this analysis, including 19 354 sources reporting 
deaths, 31 499 reporting incidence, 19 773 reporting prev-
alence, and 26 631 reporting other metrics. Each newly 
identified and obtained data source is given a unique 
identifier by a team of librarians and included in the 
Global Health Data Exchange (GHDx). The GHDx makes 
publicly available the metadata for each source included in 
GBD as well as the data, where allowed by the data 
provider. Readers can use the GHDx source tool to identify 
which sources were used for estimating any disease or 
injury outcome in any given location.
Data processing
A crucial step in the GBD analytical process is correcting 
for known bias by redistributing deaths from unspecified 
codes to more specific disease categories, and by adjusting 
data with alternative case definitions or measurement 
methods to the reference method. We highlight several 
major changes in data processing that in some cases have 
affected GBD results.
Cause of death redistribution
Vital registration with medical certification of cause of 
death is a crucial resource for the GBD cause of death 
analysis in many countries. Cause of death data obtained 
using various revisions of the International Classification 
of Diseases and Injuries (ICD)9 were mapped to the 
GBD cause list. Many deaths, however, are assigned to 
causes that cannot be the underlying cause of death 
(eg, cardiopulmonary failure) or are inadequately speci-
fied (eg, injury from undetermined intent). These deaths 
were reassigned to the most probable underlying causes 
of death as part of the data processing for GBD. 
Redistribution algorithms can be divided into three 
categories: proportionate redistribution, fixed proportion 
redistribution based on published studies or expert 
See Online for appendix 2
For the GHDx see http://ghdx.
healthdata.org
For the statistical code see 
http://ghdx.healthdata.org/gbd-
2019/code
For the GHDx source tool see 
http://ghdx.healthdata.org/gbd-
2019/data-input-sources
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judgment, or statistical algorithms. For GBD 2019, data 
for 116 million deaths attributed to multiple causes were 
analysed to produce more empirical redistribution algo-
rithms for sepsis,10 heart failure, pulmonary embolism, 
acute kidney injury, hepatic failure, acute respiratory 
failure, pneumonitis, and five intermediate causes 
(hydrocephalus, toxic encephalopathy, compres sion of 
brain, encephalopathy, and cerebral oedema) in the 
central nervous system. To redistribute unspecified 
injuries, we used a method similar to that of intermediate 
cause redistribution, using the pattern of the nature of 
injury codes in the causal chain where the ICD codes X59 
(“exposure to unspecified factor”) and Y34 (“unspecified 
event, undetermined intent”) and GBD injury causes 
were the underlying cause of death. These new 
algorithms led to important changes in the causes to 
which these inter mediate outcomes were redistributed. 
Additionally, data on deaths from diabetes and stroke 
lack the detail on subtype in many countries; we ran 
regressions on vital registration data with at least 50% 
of deaths coded specifically to type 1 or 2 diabetes and 
ischaemic, haemorrhagic, or subarachnoid stroke to 
predict deaths by these subtypes when these were coded 
to unspecified diabetes or stroke.
Correcting for non-reference case definitions or measurement 
methods
In previous cycles of GBD, data reported using alternative 
case definitions or measurement methods were corrected 
to the reference definition or measurement method 
primarily as part of the Bayesian meta-regression models. 
For example, in DisMod-MR, the population data were 
simultaneously modelled as a function of country covar-
iates for variation in true rates and as a function of 
indicator variables capturing alternative measurement 
methods. To enhance transparency and to standardise 
and improve methods in GBD 2019, we estimated 
correction factors for alternative case definitions or 
measurement methods using network meta-regression, 
including only data where two methods were assessed in 
the same location–time period or in the exact same 
population. This included validation studies where two 
methods had been compared in populations that were 
not necessarily random samples of the general popu-
lation. Details on the correction factors from alternative 
to reference measurement methods are provided in 
appendix 1 (section 4.4.2).
Clinical informatics
Clinical informatics data include inpatient admissions, 
outpatient (including general practitioner) visits, and 
health insurance claims. Several data processing steps 
were undertaken. Inpatient hospital data with a single 
diagnosis only were adjusted to account for non-
primary diagnoses as well as outpatient care. For each 
GBD cause that used clinical data, ratios of non-primary 
to primary diagnosis rates were extracted from claims 
in the USA, Taiwan (province of China), New Zealand, 
and the Philippines, as well as USA Healthcare Cost and 
Utilization Project inpatient data. Ratios of outpatient to 
inpatient care for each cause were extracted from claims 
data from the USA and Taiwan (province of China). 
The log of the ratios for each cause were modelled by 
age and sex using MR-BRT (Meta-Regression-Bayesian 
Regularised Trimmed), the Bayesian meta-regression 
tool. To account for the incomplete health-care access in 
populations where not every person with a disease or 
injury would be accounted for in administrative clinical 
records, we transformed the adjusted admission rates 
using a scalar derived from the Healthcare Access and 
Quality Index.11 We used this approach to produce 
adjusted, standardised clinical data inputs. More details 
are provided in appendix 1 (section 4.3).
Modelling
For most diseases and injuries, processed data are 
modelled using standardised tools to generate estimates 
of each quantity of interest by age, sex, location, and year. 
There are three main standardised tools: Cause of Death 
Ensemble model (CODEm), spatiotemporal Gaussian 
process regression (ST-GPR), and DisMod-MR. Previous 
publications2,3,12 and the appendix provide more details on 
these general GBD methods. Briefly, CODEm is a highly 
systematised tool to analyse cause of death data using an 
ensemble of different modelling methods for rates or 
cause fractions with varying choices of covariates that 
perform best with out-of-sample predictive validity 
testing. DisMod-MR is a Bayesian meta-regression tool 
that allows evaluation of all available data on incidence, 
prev alence, remission, and mortality for a disease, 
enforcing consistency between epidemiological para-
meters. ST-GPR is a set of regression methods that 
borrow strength between locations and over time for 
single metrics of interest, such as risk factor exposure or 
mortality rates. In addition, for select diseases, particularly 
for rarer outcomes, alternative modelling strategies 
have been dev eloped, which are described in appendix 1 
(section 3.2).
In GBD 2019, we designated a set of standard locations 
that included all countries and territories as well as 
the subnational locations for Brazil, China, India, and 
the USA. Coefficients of covariates in the three main 
modelling tools were estimated for these standard 
locations only—ie, we ignored data from subnational 
locations other than for Brazil, China, India, and the USA 
(appendix 1 section 1.1). Using this set of standard 
locations will prevent changes in regression coefficients 
from one GBD cycle to the next that are solely due to the 
addition of new subnational units in the analysis that 
might have lower quality data or small populations 
(appendix 1 section 1.1). Changes to CODEm for GBD 2019 
included the addition of count models to the model 
ensemble for rarer causes. We also modified DisMod-MR 
priors to effectively increase the out-of-sample coverage of 
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uncertainty intervals (UIs) as assessed in simulation 
testing (appendix 1 section 4.5).
For the cause Alzheimer’s disease and other dementias, 
we changed the method of addressing large variations 
between locations and over time in the assignment of 
dementia as the underlying cause of death. Based on 
a systematic review of published cohort studies, we 
estimated the relative risk of death in individuals with 
dementia. We identified the proportion of excess deaths 
in patients with dementia where dementia is the under-
lying cause of death as opposed to a correlated risk factor 
(appendix 1 section 2.6.2). We changed the strategy of 
modelling deaths for acute hepatitis A, B, C, and E from 
a natural history model relying on inpatient case fatality 
rates to CODEm models after predicting type-specific 
acute hepatitis deaths from vital registration data with 
specified hepatitis type.
DisMod-MR was used to estimate deaths from three 
outcomes (dementia, Parkinson’s, and atrial fibrillation), 
and to determine the proportions of deaths by underlying 
aetiologies of cirrhosis, liver cancer, and chronic kidney 
disease deaths.
Socio-demographic Index, annual rate of change, and 
data presentation
The Socio-demographic Index (SDI) is a composite 
indicator of a country’s lag-distributed income per 
capita, average years of schooling, and the fertility rate in 
females under the age of 25 years (appendix 1 section 6).13 
For changes over time, we present annualised rates of 
change as the difference in the natural log of the values 
at the start and end of the time interval divided by the 
number of years in the interval. We examine the 
relationship between SDI and the annualised rate of 
change in age-standardised DALY rates for all causes, 
apart from HIV/AIDS, natural disasters, and war and 
conflict, by country or territory, for the time periods 
1990–2010 and 2010–19. We deliberately subtracted out 
DALYs due to HIV/AIDS because their magnitude in 
some parts of the world would have obscured the trends 
in all other causes; we also subtracted out DALY rates 
from natural disasters and war and conflict to avoid 
trends in disease burden in some countries being 
dominated by these sudden and dramatic changes. As a 
measure of the epidemiological transition, we present 
the ratio of YLDs due to non-communicable diseases 
and injuries, and due to total burden in DALYs. We 
present 95% UIs for every metric based on the 25th and 
975th ordered values of 1000 draws of the posterior 
distribution.
Role of the funding source
The funders of this study had no role in study design, 
data collection, data analysis, data interpretation, or the 
writing of the report. The corresponding author had full 
access to the data in the study and final responsibility for 
the decision to submit for publication.
Results
Global trends
Between 1990 and 2019, the number of global DALYs 
remained almost constant, but once the effects of 
population growth and ageing were removed by con-
verting counts to age-standardised rates, there were clear 
improvements in overall health (figure 1). Over the past 
decade, the pace of decline in global age-standardised 
DALY rates accelerated in age groups younger than 
50 years compared with the 1990–2010 time period 
(table). The annualised rate of decline was greatest in the 
0–9-year age group. In the population aged 50 years and 
older, the rate of change was slower from 2010 to 2019 
compared with the earlier time period.
These general trends are made up of complex trends for 
specific diseases and injuries. Overall trends in the number 
of DALYs across the different age groups between 
1990 and 2019 are driven by some key diseases and injuries 
(figure 2). The ten most important drivers of increasing 
burden (ie, the causes that had the largest absolute 
increases in number of DALYs between 1990 and 2019) 
include six causes that largely affect older adults (ischaemic 
heart disease, diabetes, stroke, chronic kidney disease, 
lung cancer, and age-related hearing loss), whereas the 
other four causes (HIV/AIDS, other musculoskeletal 
disorders, low back pain, and depressive disorders) are 
common from teenage years into old age (figure 2). 
Despite these ten conditions contributing the largest 
number of additional DALYs over the 30-year period, only 
HIV/AIDS, other musculoskeletal disorders, and diabetes 
saw large increases in age-standardised DALY rates, with 
an increase of 58·5% (95% UI 37·1–89·2) for HIV/AIDS, 
30·7% (27·6–34·3) for other musculoskeletal disorders, 
and 24·4% (18·5–29·7) for diabetes. The burden of 
HIV/AIDS, however, peaked in 2004 and has dropped 
substantially after the global scale-up of antiretroviral 
treatment (ART). The changes in age-standardised rates 
for chronic kidney disease, age-related hearing loss, and 
Figure 1: Global DALYs and age-standardised DALY rates, 1990–2019
Shaded sections indicate 95% uncertainty intervals. DALY=disability-adjusted 
life-year.
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depressive disorders were small (figure 2). Substantial 
declines in age-standardised rates were seen in ischaemic 
heart disease (28·6%, 95% UI 24·2–33·3), stroke (35·2%, 
30·5–40·5), and lung cancer (16·1%, 8·2–24·0).
The ten most important contri butors to declining 
burden (ie, the causes that had the largest absolute 
decreases in number of DALYs between 1990 and 2019) 
include nine that predominantly affect children (lower 
respir atory infections, diarrhoeal diseases, neonatal dis-
orders, measles, protein-energy malnutrition, congenital 
birth defects, drowning, tetanus, and malaria), as well 
as tuberculosis, which largely affects adults. All of 
these causes with declining burden also had substantial 
decreases in age-standardised DALY rates, ranging 
from 32·6% (21·2–42·1) decline for neonatal disorders 
to 90·4% (87·5–92·8) decline for measles, not just 
decreases in the absolute number of DALYs due to 
demographic changes (figure 2A). Although most of the 
ten leading Level 3 causes of DALYs were the same for 
both sexes in 2019, road injuries (ranked fourth for 
males), cirrhosis (ninth), and lung cancer (tenth) were in 
the top ten for males only, and were replaced by low back 
pain (ranked sixth for females), gynaecological diseases 
(ninth), and headache disorders (tenth) for females 
(appendix 2 figure S5 and tables S2–5, S7, S8, S12, S13, 
S16). Congenital defects were ranked tenth for both sexes 
combined in 2019 but did not make the top ten for either 
sex separately.
The burden for children younger than 10 years declined 
profoundly between 1990 and 2019, by 57·5% (95% UI 
50·3–63·1). Key drivers of this progress included large 
reductions in major infectious diseases affecting 
children—namely, lower respiratory infections, diarrhoeal 
diseases, and meningitis, each of which declined by 
more than 60% between 1990 and 2019 (figure 2). In 2019, 
neonatal disorders were the leading cause of burden in 
this age group, accounting for 32·4% (30·7–34·1) of the 
group’s global DALYs, increasing from 23·0% (22·0–24·1) 
in 1990. Six infectious diseases were also among the 
top ten causes of burden in children: lower respiratory 
infections (ranked second), diarrhoeal diseases (third), 
malaria (fifth), meningitis (sixth), whooping cough (ninth), 
and sexually transmitted infections (which were fully 
accounted for by congenital syphilis in this age group; 
tenth). Congenital birth defects (ranked fourth) as well 
as two nutritional disorders—dietary iron deficiency 
(seventh) and protein-energy malnutrition (eighth)—
completed the top ten. The percentage change in age-
standardised DALY rates for eight of the ten leading 
causes was large, ranging from a 35·4% (23·8–44·8) 
decline for neonatal disorders to 78·3% (69·9–85·5) 
decline for protein-energy malnutrition over the study 
period. The decreases for the remaining two top-ten 
causes, sexually transmitted infections and dietary iron 
deficiency, were much more modest. Sub-Saharan Africa 
experienced nearly half of the total DALYs (49·9% 
[47·6–52·3]) for this age group in 2019.
The change in disease burden in adolescents aged 
10–24 years was much more modest (figure 2). DALYs 
declined by 6·2% (95% UI 2·1–10·5) overall between 
1990 and 2019. DALYs for non-communicable diseases 
increased by 13·1% (9·5–16·3), whereas injuries declined 
by 24·8% (19·7–29·3) and infectious diseases by 18·7% 
(13·4–24·0). Three injury causes were among the top ten 
causes of global DALYs in this age group in 2019: road 
injuries (ranked first), self-harm (third), and interpersonal 
violence (fifth; figure 2). Headache disor ders, two mental 
disorders (depression and anxiety), low back pain, dietary 
iron deficiency, HIV/AIDS, and diarrhoeal disease were 
the other causes in the top ten for adolescents. Among 
the top ten causes in this age group, age-standardised 
DALY rates for road injuries, self-harm, and diarrhoeal 
diseases decreased by more than a third each between 
1990 and 2019. As in the 0–9-year age group, the large 
increase in burden due to HIV/AIDS in the 10–24-year age 
group reflects a rapid increase in the first half of the study 
period followed by a decline after the global scale-up of 
ART; despite declining in recent years, the HIV/AIDs 
burden has not yet returned to 1990 levels. The other 
causes in the top ten showed small or insignificant change 
(figure 2). The sex differences in the top ten rankings are 
striking. The three previously mentioned injuries were 
the top-ranked causes of DALYs among male adolescents 
(appendix 2 figure S9), whereas headaches, depressive 
disorders, and anxiety disorders were the top three causes 
of DALYs among females (appendix 2 figure S10). 
DALYs 2019 Annualised rate of change, 1990–2010 Annualised rate of change, 2010–19
Count 
(millions)
Age-standardised rate 
(per 100 000)
DALYs Age-standardised rate DALYs Age-standardised rate
0–9 years 531 (458 to 621) 19 125·7 (16 495·1 to 22 382·5) −2·3% (−2·5 to −2·2) −2·5% (−2·6 to −2·3) −3·7% (−4·4 to −2·9) −4·0% (−4·7 to −3·2)
10–24 years 229 (194 to 270) 12 313·0 (10 399·9 to 14 478·3) 0·2% (0·1 to 0·2) −0·7% (−0·8 to −0·6) −1·1% (−1·4 to −0·9) −1·3% (−1·5 to −1·1)
25–49 years 616 (533 to 709) 22 691·2 (19 613·7 to 26 116·3) 1·4% (1·4 to 1·5) −0·4% (−0·4 to −0·3) −0·0% (−0·2 to 0·1) −1·2% (−1·4 to −1·0)
50–74 years 832 (752 to 919) 28 263·2 (25 527·6 to 31 213·4) 1·3% (1·2 to 1·3) −1·0% (−1·0 to −0·9) 2·0% (1·8 to 2·1) −0·9% (−1·1 to −0·8)
≥75 years 329 (308 to 351) 77 320·5 (72 372·5 to 82 440·3) 2·2% (2·2 to 2·2) −0·9% (−0·9 to −0·9) 2·3% (2·3 to 2·4) −0·8% (−0·9 to −0·8)
All ages 2540 (2290 to 2810) 32 801·7 (29 535·1 to 36 319·5) −0·0% (−0·1 to 0·0) −1·4% (−1·5 to −1·3) −0·2% (−0·4 to 0·0) −1·3% (−1·5 to −1·1)
DALY=disability-adjusted life-year.
Table: Global DALYs in 2019 and annualised rate of change in DALYs and age-standardised DALY rates over 1990–2010 and 2010–19, by age group and for all ages
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(Figure 2 continues on next page)
Leading causes 1990 Percentage of DALYs
1990
Leading causes 2019 Percentage of DALYs
2019
Percentage change in
number of DALYs,
1990–2019
Percentage change in
age-standardised DALY 
rate, 1990–2019
A All ages
B 0–9 years
Communicable, maternal, neonatal, and nutritional diseases  
Non-communicable diseases 
Injuries
1 Neonatal disorders 10·6 (9·9 to 11·4) 1 Neonatal disorders 7·3 (6·4 to 8·4)
2 Lower respiratory infections 8·7 (7·6 to 10·0) 2 Ischaemic heart disease 7·2 (6·5 to 7·9)
3 Diarrhoeal diseases 7·3 (5·9 to 8·8) 3 Stroke 5·7 (5·1 to 6·2)
4 Ischaemic heart disease 4·7 (4·4 to 5·0) 4 Lower respiratory infections 3·8 (3·3 to 4·3)
5 Stroke 4·2 (3·9 to 4·5) 5 Diarrhoeal diseases 3·2 (2·6 to 4·0)
6 Congenital birth defects 3·2 (2·3 to 4·8) 6 COPD 2·9 (2·6 to 3·2)
7 Tuberculosis 3·1 (2·8 to 3·4) 7 Road injuries 2·9 (2·6 to 3·0) –31·0 (–37·1 to –25·4)
8 Road injuries 2·7 (2·6 to 3·0) 8 Diabetes 2·8 (2·5 to 3·1)
9 Measles 2·7 (0·9 to 5·6) 9 Low back pain 2·5 (1·9 to 3·1)
10 Malaria 2·5 (1·4 to 4·1) 10 Congenital birth defects 2·1 (1·7 to 2·6)
11 COPD 2·3 (1·9 to 2·5)
2·0 (1·6 to 2·7)
11 HIV/AIDS 1·9 (1·6 to 2·2)
12 Protein-energy malnutrition 12 Tuberculosis 1·9 (1·7 to 2·0)
13 Low back pain 1·7 (1·2 to 2·1) 13 Depressive disorders
14 Self-harm 1·4 (1·2 to 1·5) 14 Malaria 1·8 (0·9 to 3·1)
15 Cirrhosis 1·3 (1·2 to 1·5) 15 Headache disorders
16 Meningitis 1·3 (1·1 to 1·5) 16 Cirrhosis 1·8 (1·6 to 2·0)
17 Drowning 1·3 (1·1 to 1·4)
1·1 (0·2 to 2·4)
1·1 (0·8 to 1·5)
17 Lung cancer 1·8 (1·6 to 2·0)
18 Headache disorders 18 Chronic kidney disease
19 Depressive disorders 19 Other musculoskeletal
20 Diabetes 1·1 (1·0 to 1·2) 20 Age-related hearing loss
21 Lung cancer 1·0 (1·0 to 1·1) 21 Falls 1·5 (1·4 to 1·7)
22 Falls 1·0 (0·9 to 1·2)
1·0 (0·7 to 1·3)
0·9 (0·9 to 1·0)
22 Self-harm 1·3 (1·2 to 1·5) –38·9 (–44·3 to –33·0)
23 Dietary iron deficiency 23 Gynaecological diseases 1·2 (0·9 to 1·5)
24 Interpersonal violence 24 Anxiety disorders 1·1 (0·8 to 1·5)
25 Whooping  cough 0·9 (0·4 to 1·7)
0·8 (0·6 to 1·1)
0·8 (0·8 to 0·9)
25 Dietary iron deficiency
27 Age-related hearing loss 26 Interpersonal violence –23·8 (–28·6 to –17·8)
29 Chronic kidney disease 40 Meningitis 0·6 (0·5 to 0·8)
30 HIV/AIDS 0·8 (0·6 to 1·0) 41 Protein-energy malnutrition
32 Gynaecological diseases 0·8 (0·6 to 1·0) 46 Drowning 0·5 (0·5 to 0·6)
34 Anxiety disorders 0·7 (0·5 to 1·0)
0·7 (0·5 to 1·0)
55 Whooping  cough 0·4 (0·2 to 0·7)
35 Other musculoskeletal 71 Measles 0·3 (0·1 to 0·6)
1 Neonatal disorders 23·0 (22·0 to 24·1) 1 Neonatal disorders 32·4 (30·7 to 34·1)
2 Lower respiratory infections 17·0 (14·9 to 19·7) 2 Lower respiratory infections 11·6 (10·5 to 12·6)
3 Diarrhoeal diseases 13·1 (10·7 to 15·1) 3 Diarrhoeal diseases 9·3 (7·9 to 10·8)
4 Congenital birth defects 6·6 (4·6 to 10·0) 4 Congenital birth defects 8·6 (7·4 to 10·7)
5 Measles 5·7 (2·0 to 11·8) 5 Malaria 6·4 (3·3 to 10·8)
6 Malaria 4·6 (2·5 to 7·5)
4·1 (3·1 to 5·5)
6 Meningitis 2·1 (1·8 to 2·5)
7 Protein-energy malnutrition 7 Dietary iron deficiency –8·2 (–12·3 to –4·1)
8 Meningitis 2·3 (2·0 to 2·7) 8 Protein-energy malnutrition
9 Whooping cough 1·9 (0·8 to 3·8) 9 Whooping cough 1·9 (0·9 to 3·3)
10 Drowning 1·8 (1·5 to 2·1) 10 STIs 1·4 (0·5 to 2·8)
11 Tuberculosis 1·8 (1·5 to 2·1) 11 Measles 1·3 (0·4 to 2·7)
12 Tetanus 1·7 (1·4 to 1·9) 12 Road injuries 1·1 (1·0 to 1·4)
13 Road injuries 1·3 (1·1 to 1·5)
0·9 (0·6 to 1·3)
13 Tuberculosis 1·0 (0·9 to 1·2)
14 Dietary iron deficiency 14 HIV/AIDS 1·0 (0·9 to 1·2)
15 STIs 0·7 (0·2 to 1·5) 15 iNTS 1·0 (0·6 to 1·5)
16 Typhoid and paratyphoid 0·7 (0·3 to 1·3) 16 Drowning 0·9 (0·8 to 1·1)
17 Foreign body 0·6 (0·5 to 0·7) 17 Haemoglobinopathies 0·9 (0·7 to 1·0)
18 HIV/AIDS 0·6 (0·5 to 0·7) 18 Typhoid and paratyphoid 0·8 (0·4 to 1·5)
19 Encephalitis 0·5 (0·4 to 0·7) 19 Asthma 0·5 (0·4 to 0·8)
20 Acute hepatitis 0·5 (0·4 to 0·5) 20 Foreign body 0·5 (0·4 to 0·5)
21 Haemoglobinopathies 0·4 (0·3 to 0·6) 21 EMBID 0·5 (0·4 to 0·6)
22 Leukaemia 0·4 (0·3 to 0·6) 22 Sudden infant death 0·5 (0·2 to 1·0)
23 Sudden infant death 0·4 (0·2 to 0·9) 23 Idiopathic epilepsy 0·5 (0·3 to 0·6)
24 Asthma 0·4 (0·3 to 0·5) 24 Other unspecified infectious
25 Falls 0·4 (0·3 to 0·5) 25 Dermatitis 0·4 (0·2 to 0·7) –6·0 (–6·9 to –5·1)
28 Idiopathic epilepsy 0·3 (0·2 to 0·4)
0·3 (0·2 to 0·4)
26 Leukaemia 0·4 (0·4 to 0·5)
30 Other unspecified infectious 27 Falls 0·4 (0·3 to 0·5)
33 iNTS 0·3 (0·1 to 0·4) 28 Encephalitis 0·4 (0·3 to 0·5)
34 EMBID 0·3 (0·2 to 0·3) 32 Tetanus 0·3 (0·3 to 0·5)
44 Dermatitis 0·2 (0·1 to 0·3) 39 Acute hepatitis 0·3 (0·2 to 0·3)
–35·4 (–44·8 to –23·8)
–69·6 (–76·3 to –61·6)
–68·5 (–75·9 to –58·4)
–40·1 (–55·1 to –17·9)
–38·5 (–63·1 to –6·5)
–61·0 (–69·2 to –51·1)
–78·3 (–85·5 to –69·9)
–53·2 (–75·6 to –20·4)
–14·9 (–30·1 to 2·5)
–90·5 (–92·9 to –87·6)
–63·7 (–70·8 to –48·8)
–75·5 (–80·6 to –69·2)
–25·0 (–35·3 to –13·6)
61·4 (20·6 to 109·3)
–79·0 (–82·6 to –72·2)
–13·7 (–34·3 to 14·7)
–50·7 (–62·5 to –36·9)
–37·5 (–50·0 to –21·5)
–63·6 (–70·2 to –57·1)
–22·1 (–36·1 to –6·0)
–46·9 (–61·7 to –30·0)
–34·0 (–49·1 to –3·8)
–29·3 (–50·3 to 3·3)
–55·3 (–69·5 to –37·0)
–48·3 (–68·7 to –22·6)
–68·5 (–77·9 to –50·2)
–91·2 (–93·8 to –85·6)
–74·1 (–82·6 to –61·1)
–36·2 (–45·4 to –24·7)
–69·1 (–75·9 to –60·9)
–67·8 (–75·3 to –57·2)
–41·6 (–54·6 to –17·4)
–36·9 (–61·4 to –2·2)
–59·7 (–68·1 to –49·3)
–0·8 (–5·3 to 3·6)
–78·1 (–85·0 to –68·9)
–54·7 (–74·7 to –17·3)
–16·3 (–30·7 to 1·7)
–90·0 (–92·6 to –86·9)
–61·5 (–68·7 to –45·0)
–74·5 (–79·8 to –67·8)
–18·6 (–35·6 to 3·6)
68·3 (27·4 to 121·2)
–77·6 (–81·3 to –70·1)
–10·3 (–30·3 to 22·5)
–46·7 (–59·1 to –31·1)
–32·2 (–46·2 to –14·5)
–62·9 (–69·6 to –56·2)
–18·9 (–33·3 to –0·9)
–50·6 (–61·6 to –29·8)
–30·7 (–45·8 to 3·6)
–28·4 (–48·3 to 7·8)
2·7 (1·7 to 3·7)
–54·8 (–67·7 to –32·9)
–47·2 (–67·0 to –18·0)
–67·6 (–76·7 to –47·6)
–91·3 (–93·8 to –85·6)
–73·1 (–81·7 to –59·1)
2·0 (1·3 to 2·9)
2·0 (1·7 to 2·3)
0·4 (0·3 to 0·6)
–57·2 (–64·4 to –48·6)
–74·5 (–82·0 to –64·5)
–68·2 (–71·9 to –62·8)
–56·3 (–75·6 to –20·3)
–90·4 (–92·8 to –87·5)
–6·8 (–8·7 to –4·9)
–0·1 (–1·0 to 0·7)
–16·4 (–18·7 to –14·0)
–14·5 (–22·5 to –7·4)
–1·8 (–3·7 to –0·1)
30·7 (27·6 to 34·3)
6·3 (0·2 to 12·4)
–16·2 (–24·0 to –8·2)
–26·8 (–32·5 to –19·0)
1·1 (–4·2 to 2·9)
–37·8 (–61·9 to –6·2)
–1·8 (–2·9 to –0·8)
–62·8 (–66·6 to –58·0)
58·5 (37·1 to 89·2)
–40·0 (–52·7 to –17·1)
–16·3 (–17·1 to –15·5)
24·4 (18·5 to 29·7)
–39·8 (–44·9 to –30·2)
–64·6 (–71·7 to –54·2)
–62·5 (–69·0 to –54·9)
–35·2 (–40·5 to –30·5)
–28·6 (–33·3 to –24·2)
–32·6 (–42·1 to –21·2)–32·3 (–41·7 to –20·8)
50·4 (39·9 to 60·2)
32·4 (22·0 to 42·2)
–56·7 (–64·2 to –47·5)
–57·5 (–66·2 to –44·7)
25·6 (15·1 to 46·0)
2·4 (–6·9 to 10·8)
147·9 (135·9 to 158·9)
46·9 (43·3 to 50·5)
–37·3 (–50·6 to –12·8)
127·7 (97·3 to 171·7)
–41·0 (–47·2 to –33·5)
61·1 (56·9 to 65·0)
–29·4 (–56·9 to 6·6)
56·7 (52·4 to 62·1)
33·0 (22·4 to 48·2)
69·1 (53·1 to 85·4)
93·2 (81·6 to 105·0)
128·9 (122·0 to 136·3)
82·8 (75·2 to 88·9)
47·1 (31·5 to 61·0)
–5·6 (–14·2 to 3·7)
48·7 (45·8 to 51·8)
53·7 (48·8 to 59·1)
13·8 (10·5 to 17·2)1·1 (0·8 to 1·5)
1·6 (1·2 to 2·1)
1·6 (1·2 to 2·1)
1·6 (1·5 to 1·8)
1·8 (0·4 to 3·8)
1·8 (1·4 to 2·4)
–89·8 (–92·3 to –86·8)
–54·5 (–74·6 to –16·9)
–60·6 (–65·2 to –53·6)
–71·1 (–79·6 to –59·7)
–51·3 (–59·4 to –42·0)
10·2 (3·2 to 19·2)1·1 (1·0 to 1·2)
0·6 (0·5 to 0·7)
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Maternal disorders, gynaecological disorders, and dietary 
iron deficiency were also in the top ten causes for females 
in this relatively young age group (appendix 2 figure S10).
Five causes that were in the top ten for ages 10–24 
in 2019 were also in the top ten in the 25–49 age group: 
road injuries (ranked first), HIV/AIDS (second), low back 
pain (fourth), headache disorders (fifth), and depressive 
disorders (sixth; figure 2). Tuberculosis and four non-
communicable causes—ischaemic heart disease, gynae-
cological disorders, other musculoskeletal disor ders, and 
stroke—completed the top ten rankings. There were 
substantial improvements since 1990 in DALY rates of 
(Figure 2 continues on next page)
Leading causes 1990 Percentage of DALYs
1990
Leading causes 2019 Percentage of DALYs
2019
Percentage change in
number of DALYs,
1990–2019
Percentage change in
age-standardised DALY 
rate, 1990–2019
C 10–24 years
D 25–49 years
Communicable, maternal, neonatal, and nutritional diseases  
Non-communicable diseases 
Injuries
1 Road injuries 7·8 (6·9 to 8·8) 1 Road injuries 6·6 (5·6 to 7·7)
2 Self-harm 4·9 (4·1 to 5·6) 2 Headache disorders 5·0 (0·6 to 10·9)
3 Headache disorders 3·8 (0·4 to 8·2) 3 Self-harm 3·7 (3·1 to 4·5)
4 Tuberculosis 3·6 (3·1 to 4·1) 4 Depressive disorders 3·7 (2·6 to 5·0)
5 Diarrhoeal diseases 3·2 (2·1 to 4·9) 5 Interpersonal violence –15·4 (–21·3 to –7·9)
6 Interpersonal violence 6 Anxiety disorders 3·3 (2·3 to 4·4)
7 Maternal disorders 3·0 (2·6 to 3·4) 7 Low back pain 3·2 (2·2 to 4·3) –12·0 (–13·3 to –10·6)
8 Depressive disorders 2·8 (2·0 to 3·9) 8 Dietary iron deficiency –3·5 (–9·5 to 2·0)
9 Low back pain 2·8 (1·9 to 3·8) 9 HIV/AIDS 2·6 (1·9 to 3·5)
10 Drowning 2·7 (2·3 to 3·2) 10 Diarrhoeal diseases 2·6 (1·9 to 3·6)
11 Typhoid and paratyphoid 2·6 (1·2 to 4·9) 11 Neonatal disorders 2·3 (1·8 to 2·8)
12 Anxiety disorders 2·6 (1·8 to 3·5) 12 Tuberculosis 2·1 (1·8 to 2·5)
13 Dietary iron deficiency 13 Gynaecological diseases 1·9 (1·4 to 2·6)
14 Malaria 2·1 (1·3 to 3·3) 14 Typhoid and paratyphoid 1·8 (0·8 to 3·3)
15 Lower respiratory infections 1·7 (1·4 to 2·0) 15 Maternal disorders 1·8 (1·5 to 2·2)
16 Conflict and terrorism 1·5 (1·3 to 1·9) 16 Malaria 1·8 (1·0 to 3·0)
17 Gynaecological diseases 1·5 (1·1 to 2·1) 17 Conduct disorder 1·8 (1·1 to 2·6)
18 Falls 1·5 (1·3 to 1·6) 18 Drug use disorders 1·6 (1·3 to 2·1)
19 Congenital birth defects 1·5 (1·3 to 1·7) 19 Acne vulgaris 1·6 (1·0 to 2·4)
20 Idiopathic epilepsy 1·4 (1·1 to 1·8) 20 Idiopathic epilepsy 1·6 (1·2 to 2·1) –11·4 (–22·8 to 4·6)
21 Conduct disorder 1·3 (0·8 to 2·0) 21 Congenital birth defects 1·5 (1·3 to 1·7) –21·2 (–29·7 to –10·5)
22 Drug use disorders 1·3 (1·0 to 1·6) 22 Falls 1·4 (1·3 to 1·6) –23·9 (–30·9 to –16·7)
23 Asthma 1·2 (1·0 to 1·6) 23 Drowning 1·4 (1·2 to 1·7)
24 Stroke 1·2 (1·0 to 1·3) 24 Lower respiratory infections 1·4 (1·2 to 1·7)
25 Meningitis 1·1 (1·0 to 1·3) 25 Age-related hearing loss
27 Acne vulgaris 1·1 (0·7 to 1·6) 27 Asthma 1·3 (1·0 to 1·8) –18·0 (–23·8 to –12·4)
28 Age-related hearing loss 30 Stroke 1·1 (0·9 to 1·3)
33 HIV/AIDS 0·9 (0·6 to 1·5) 34 Meningitis 0·9 (0·7 to 1·1)
35 Neonatal disorders 0·9 (0·7 to 1·1) 46 Conflict and terrorism 0·6 (0·5 to 0·8)
1 Road injuries 5·6 (5·1 to 6·1) 1 Road injuries 5·1 (4·6 to 5·7)
2 Tuberculosis 5·5 (4·8 to 6·2) 2 HIV/AIDS 4·8 (4·0 to 5·9)
3 Ischaemic heart disease 4·4 (3·8 to 4·9) 3 Ischaemic heart disease 4·7 (4·0 to 5·4)
4 Low back pain 3·9 (2·9 to 5·1) 4 Low back pain 3·9 (2·9 to 5·0)
5 Self-harm 3·8 (3·3 to 4·4) 5 Headache disorders 3·7 (0·8 to 7·7)
6 Stroke 3·5 (3·1 to 3·9) 6 Depressive disorders 3·5 (2·5 to 4·5)
7 Headache disorders 3·1 (0·7 to 6·4) 7 Gynaecological diseases 3·3 (2·5 to 4·2)
8 Depressive disorders 3·0 (2·2 to 3·9) 8 Other musculoskeletal
9 Cirrhosis 2·8 (2·5 to 3·2) 9 Stroke 3·2 (2·8 to 3·6) –31·0 (–37·9 to –24·6)
10 Gynaecological diseases 2·8 (2·2 to 3·7) 10 Tuberculosis 3·0 (2·6 to 3·4)
11 Maternal disorders 2·6 (2·3 to 2·9) 11 Self-harm 2·9 (2·4 to 3·4) –37·2 (–43·2 to –30·9)
12 Interpersonal violence 12 Cirrhosis 2·8 (2·4 to 3·2)
13 HIV/AIDS 2·3 (1·6 to 3·2) 13 Interpersonal violence
14 Other musculoskeletal 14 Diabetes 2·2 (1·9 to 2·5)
15 Diarrhoeal diseases 2·0 (1·3 to 3·1) 15 Anxiety disorders 2·0 (1·4 to 2·7)
16 Falls 1·8 (1·6 to 2·0) 16 Drug use disorders 1·9 (1·5 to 2·2)
17 Anxiety disorders 1·7 (1·2 to 2·2) 17 Falls 1·8 (1·6 to 2·0)
18 Alcohol use disorders 18 Chronic kidney disease
19 Neck pain 1·3 (0·9 to 2·0) 19 Neck pain 1·6 (1·1 to 2·4)
20 Diabetes 1·3 (1·2 to 1·5) 20 Alcohol use disorders
21 Chronic kidney disease 21 Age-related hearing loss
22 Drug use disorders 1·3 (1·0 to 1·6) 22 Schizophrenia 1·5 (1·1 to 1·9)
23 Schizophrenia 1·3 (0·9 to 1·6) 23 Maternal disorders 1·4 (1·2 to 1·6)
24 Age-related hearing loss 24 Diarrhoeal diseases 1·3 (1·0 to 1·9)
25 Lower respiratory infections 1·2 (1·1 to 1·4) 25 Oral disorders 1·2 (0·7 to 2·1)
32 Oral disorders 1·0 (0·5 to 1·6) 27 Lower respiratory infections 1·2 (1·0 to 1·4) –23·1 (–30·2 to –16·0)
2·8 (0·5 to 5·1)
–46·2 (–59·0 to –29·6)
–53·4 (–60·5 to –47·2)
–0·9 (–2·0 to 0·2)
–0·5 (–3·1 to 1·9)
–20·9 (–24·2 to –17·9)
–3·6 (–6·0 to –1·5)
0·7 (–7·3 to 8·4)
–18·0 (–23·4 to –13·5)
25·4 (19·3 to 31·6)
1·1 (0·0 to 2·1)
29·2 (21·1 to 36·0)
–24·4 (–29·0 to –19·0)
–23·8 (–30·1 to –15·1)
–55·5 (–60·2 to –50·5)
26·7 (23·4 to 30·5)
–4·5 (–6·3 to –2·5)
–4·9 (–6·4 to –3·4)
0·2 (–3·7 to 2·3)
–19·2 (–20·5 to –18·0)
–18·5 (–26·7 to –10·1)
72·2 (52·4 to 91·9)
–22·5 (–30·1 to –16·2)
–68·5 (–71·6 to –65·1)
–38·3 (–45·0 to –30·4)
–27·6 (–34·8 to –19·4)
–1·2 (–5·7 to 3·2)
–34·1 (–41·6 to –25·5)
–58·8 (–63·2 to –53·9)
18·1 (16·7 to 19·5)
0·6 (–4·8 to 6·2)
4·4 (2·3 to 6·3)
–31·9 (–59·0 to –3·6)
–52·5 (–60·2 to –45·3)
–46·2 (–54·9 to –38·5)
–1·4 (–4·2 to 1·0)
–53·8 (–59·1 to –47·7)
103·6 (78·4 to 128·5)
–37·0 (–50·2 to –17·0)
112·8 (84·3 to 141·9)
–2·0 (–3·8 to –0·1)
0·0 (–2·8 to 2·4)
–40·5 (–47·2 to –32·8)
3·3 (0·2 to 5·6)
–33·6 (–40·4 to –27·7)–20·1 (–28·3 to –12·9)
24·6 (20·6 to 27·1)
–28·4 (–36·3 to –18·9)
20·7 (17·4 to 23·5)
2·1 (–5·0 to 11·1)
17·9 (15·7 to 20·3)
6·0 (4·4 to 7·6)
15·9 (8·6 to 22·4)
159·0 (115·4 to 211·1)
–25·7 (–40·1 to –0·3)
143·6 (114·3 to 174·6)
–44·3 (–50·7 to –36·9)
19·1 (15·8 to 22·0)
–35·5 (–46·0 to –26·4)
–42·7 (–51·9 to –33·8)
–19·4 (–50·8 to 15·8)
24·7 (22·2 to 27·0)
21·8 (15·2 to 28·7)
41·5 (39·8 to 43·2)
6·5 (–7·1 to 25·7)
–5·6 (–15·6 to 7·4)
–8·4 (–16·9 to 0·4)
–50·7 (–55·9 to –44·7)
–20·9 (–29·9 to –10·5)
18·6 (13·4 to 24·2)1·3 (0·9 to 1·8)
2·6 (1·9 to 3·4)
3·5 (2·9 to 4·1)
–1·1 (–8·3 to 5·1)
–12·8 (–21·5 to –2·9)
–26·0 (–34·0 to –16·4)
–62·1 (–65·7 to –57·9)
23·2 (11·1 to 33·2)
176·2 (131·1 to 244·3)
42·7 (28·4 to 57·3)
33·0 (29·2 to 36·9)
61·2 (56·5 to 64·5)
53·2 (49·3 to 56·8)
52·7 (49·7 to 56·0)
107·1 (101·0 to 114·3)
19·9 (8·0 to 31·1)
–27·0 (–34·7 to –18·7)
–0·9 (–10·3 to 9·1)
29·6 (19·0 to 44·5)
18·1 (10·7 to 26·5)
123·9 (110·1 to 135·3)
61·6 (57·5 to 65·4)
92·0 (82·7 to 102·5)
34·4 (25·8 to 41·7)
67·3 (53·9 to 80·3)
60·2 (52·4 to 67·9)
28·2 (22·9 to 33·2)
64·3 (58·7 to 69·1)
59·6 (57·5 to 61·9)
–28·9 (–39·6 to –19·2)
–13·5 (–32·6 to 15·5)
70·7 (66·4 to 74·1)
1·5 (1·1 to 2·1)
1·6 (1·3 to 1·9)
1·6 (1·4 to 1·8)
2·3 (2·0 to 2·6)
3·2 (2·3 to 4·2)
26·8 (15·2 to 38·5)
3·2 (2·8 to 3·6)
2·1 (1·6 to 2·8)
1·1 (0·7 to 1·5)
2·5 (2·3 to 2·8)
2·0 (1·5 to 2·8)
1·7 (1·4 to 2·0)
1·3 (0·9 to 1·7)
1·3 (1·2 to 1·4)
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Figure 2: Leading 25 Level 3 causes of global DALYs and percentage of total DALYs (1990 and 2019), and percentage change in number of DALYs and 
age-standardised DALY rates from 1990 to 2019 for both sexes combined for all ages (A), children younger than 10 years (B), and ages 10–24 years (C), 
25–49 years (D), 50–74 years (E), and 75 years and older (F)
Causes are connected by lines between time periods; solid lines are increases in rank and dashed lines are decreases. Age-related hearing loss=age-related and other 
hearing loss. Alzheimer’s disease=Alzheimer’s disease and other dementias. Atrial fibrillation=atrial fibrillation and flutter. Cirrhosis=cirrhosis and other chronic liver 
diseases. COPD=chronic obstructive pulmonary disease. EMBID=endocrine, metabolic, blood, and immune disorders. DALY=disability-adjusted life-year. iNTS=invasive 
non-typhoidal salmonella. Haemoglobinopathies=haemoglobinopathies and haemolytic anaemias. Lung cancer=tracheal, bronchus, and lung cancer. Other 
musculoskeletal=other musculoskeletal disorders. Other unspecified infectious=other unspecified infectious diseases. Sudden infant death=sudden infant death 
syndrome. STI=sexually transmitted infections excluding HIV.
Leading causes 1990 Percentage of DALYs
1990
Leading causes 2019 Percentage of DALYs
2019
Percentage change in
number of DALYs,
1990–2019
Percentage change in
age-standardised DALY 
rate, 1990–2019
E 50–74 years
F 75 years and older
Communicable, maternal, neonatal, and nutritional diseases  
Non-communicable diseases 
Injuries
1 Ischaemic heart disease 12·5 (11·6 to 13·4) 1 Ischaemic heart disease 11·8 (10·7 to 12·9)
2 Stroke 10·9 (10·0 to 11·8) 2 Stroke 9·3 (8·5 to 10·1)
3 COPD 6·5 (5·5 to 7·1) 3 Diabetes 5·1 (4·6 to 5·7)
4 Tuberculosis 4·0 (3·6 to 4·4) 4 COPD 4·7 (4·2 to 5·2) –45·9 (–51·4 to –36·2)
5 Lung cancer 3·6 (3·3 to 3·9) 5 Lung cancer 3·9 (3·4 to 4·3)
6 Diabetes 3·1 (2·8 to 3·4) 6 Low back pain 3·1 (2·3 to 4·0)
7 Cirrhosis 2·8 (2·6 to 3·1) 7 Cirrhosis 2·7 (2·4 to 3·0)
8 Low back pain 2·8 (2·1 to 3·7) 8 Chronic kidney disease
9 Diarrhoeal diseases 2·6 (1·6 to 4·0) 9 Age-related hearing loss
10 Stomach cancer 2·4 (2·2 to 2·6) 10 Road injuries 2·1 (1·9 to 2·3)
11 Road injuries 1·9 (1·8 to 2·0) 11 Other musculoskeletal
12 Lower respiratory infections 1·8 (1·6 to 2·0) 12 Tuberculosis 1·9 (1·7 to 2·1)
13 Age-related hearing loss 13 Lower respiratory infections 1·8 (1·6 to 1·9)
14 Chronic kidney disease 14 Depressive disorders
15 Asthma 1·5 (1·2 to 1·9) 15 Colorectal cancer 1·7 (1·6 to 1·9)
16 Hypertensive heart disease 16 Falls 1·7 (1·5 to 2·0)
17 Falls 1·4 (1·3 to 1·6) 17 Stomach cancer 1·7 (1·5 to 1·9) –48·1 (–536 to –42·0)
18 Colorectal cancer 1·4 (1·3 to 1·5) 18 Osteoarthritis 1·5 (0·8 to 2·9)
19 Depressive disorders 19 Blindness and vision loss
20 Blindness and vision loss 20 Breast cancer 1·4 (1·3 to 1·5)
21 Liver cancer 1·2 (1·0 to 1·3) 21 Diarrhoeal diseases 1·4 (0·9 to 2·1)
22 Breast cancer 1·2 (1·1 to 1·2) 22 Hypertensive heart disease
23 Oesophageal cancer 1·1 (0·9 to 1·2) 23 Headache disorders
24 Osteoarthritis 1·1 (0·6 to 2·2) 24 Oral disorders 1·2 (0·8 to 1·8)
25 Self-harm 1·1 (1·0 to 1·2) 25 Neck pain 1·1 (0·7 to 1·7)
26 Other musculoskeletal 27 Oesophageal cancer 1·0 (0·9 to 1·1)
28 Oral disorders 1·0 (0·6 to 1·5) 28 Asthma 1·0 (0·8 to 1·1)
29 Headache disorders 29 Liver cancer 0·9 (0·8 to 1·0) –39·9 (–48·5 to –29·5)
32 Neck pain 0·8 (0·5 to 1·2) 31 Self-harm 0·9 (0·8 to 1·0)
1 Ischaemic heart disease 18·6 (17·1 to 19·7) 1 Ischaemic heart disease 16·2 (14·6 to 17·6)
2 Stroke 15·5 (14·3 to 16·7) 2 Stroke 13·0 (11·7 to 14·0)
3 COPD 9·9 (8·6 to 10·7) 3 COPD 8·5 (7·5 to 9·2)
4 Alzheimer's disease 3·8 (1·7 to 8·6) 4 Alzheimer's disease 5·6 (2·6 to 12·2)
5 Lower respiratory infections 3·3 (3·0 to 3·6) 5 Diabetes 4·0 (3·6 to 4·3)
6 Diarrhoeal diseases 3·1 (2·0 to 4·5) 6 Lower respiratory infections 3·3 (2·9 to 3·6)
7 Diabetes 2·6 (2·4 to 2·9) 7 Lung cancer 2·6 (2·3 to 2·8)
8 Hypertensive heart disease 8 Falls 2·6 (2·2 to 2·9)
9 Age-related hearing loss 9 Chronic kidney disease
10 Lung cancer 1·9 (1·8 to 2·0) 10 Age-related hearing loss
11 Falls 1·8 (1·6 to 2·1) 11 Hypertensive heart disease
12 Tuberculosis 1·8 (1·6 to 2·1) 12 Diarrhoeal diseases 1·9 (1·2 to 3·0)
13 Low back pain 1·7 (1·2 to 2·3) 13 Low back pain 1·8 (1·3 to 2·4)
14 Chronic kidney disease 14 Colorectal cancer 1·7 (1·5 to 1·8)
15 Stomach cancer 1·6 (1·4 to 1·7) 15 Blindness and vision loss
16 Blindness and vision loss 16 Atrial fibrillation 1·3 (1·1 to 1·5)
17 Colorectal cancer 1·4 (1·3 to 1·5) 17 Stomach cancer 1·3 (1·1 to 1·4)
18 Asthma 1·2 (1·0 to 1·7) 18 Prostate cancer 1·1 (1·0 to 1·4)
19 Cirrhosis 1·2 (1·0 to 1·3) 19 Cirrhosis 1·1 (1·0 to 1·2)
20 Prostate cancer 1·0 (0·8 to 1·2) 20 Parkinson's disease
21 Atrial fibrillation 1·0 (0·8 to 1·2) 21 Osteoarthritis 1·1 (06 to 21)
22 Osteoarthritis 0·9 (0·5 to 1·7) 22 Oral disorders 0·9 (0·6 to 1·3)
23 Oral disorders 0·8 (0·6 to 1·2) 23 Tuberculosis 0·9 (0·8 to 1·0)
24 Parkinson's disease 24 Asthma 0·8 (0·7 to 1·0) –46·2 (–55·9 to –39·8)
25 Upper digestive diseases 0·8 (0·7 to 0·9) 25 Road injuries 0·8 (0·7 to 0·9)
26 Road injuries 0·7 (0·6 to 0·8) 32 Upper digestive diseases 0·6 (0·5 to 0·6)
1·7 (1·2 to 2·3)
1·6 (1·4 to 1·7)
1·5 (1·2 to 1·7)
1·3 (0·9 to 1·7)
1·2 (0·9 to 1·6)
1·1 (0·7 to 1·5)
0·9 (0·3 to 1·9)
–41·0 (–45·5 to –34·5)
–51·8 (–58·3 to –46·0)
–32·1 (–41·9 to –16·1)
5·7 (3·0 to 8·5)
–7·4 (–9·6 to –5·1)
–1·2 (–7·4 to 2·3)
–33·8 (–41·7 to –23·4)
–61·0 (–72·1 to –45·8)
–9·5 (–16·9 to –2·5)
–8·6 (–12·0 to –5·0)
4·1 (28 to 5·4)
38·2 (18·9 to 71·9)
–1·3 (–14·3 to 11·2)
22·2 (5·2 to 44·0)
20·4 (11·3 to 33·7)
115·9 (110·5 to 122·2)
90·5 (86·0 to 94·7)
102·5 (88·7 to 108·2)
36·7 (20·8 to 58·8)
–21·0 (–42·4 to 11·9)
85·0 (69·9 to 99·4)
88·8 (81·9 to 95·8)
113·6 (110·9 to 116·4)
6·3 (–5·0 to 18·9)
–8·4 (–14·1 to –2·6)
–5·1 (–12·1 to 1·2)
1·5 (0·2 to 2·9)
–27·5 (–33·3 to –21·5)
–64·7 (–68·9 to –59·4)
33·6 (280 to 40·2)
–15·2 (–23·2 to –9·9)
–2·6 (–4·9 to –0·5)
12·1 (3·7 to 19·5)
–29·1 (–34·7 to –23·0)
–15·9 (–16·9 to –14·9)
–19·8 (–27·3 to –12·1)
24·5 (18·5 to 30·4)
–36·3 (–42·1 to –30·8)
–29·1 (–34·2 to –24·1)46·1 (35·6 to 56·4)
31·5 (19·5 to 42·9)
156·1 (143·4 to 167·9)
12·0 (0·9 to 32·3)
64·3 (48·8 to 80·2)
72·1 (70·0 to 74·3)
44·6 (33·2 to 57·1)
130·2 (113·0 to 145·6)
100·8 (96·0 to 104·9)
72·9 (56·5 to 83·9)
172·0 (160·6 to 187·4)
–27·8 (–36·2 to –16·9)
49·8 (37·9 to 62·4)
107·3 (104·7 to 110·1)
95·1 (80v8 to 108·2)
88·3 (76·5 to 100·0)
1·2 (0·4 to 2·5)
1·3 (1·0 to 1·5)
1·4 (1·1 to 2·0)
1·7 (1·3 to 2·3)
1·9 (1·4 to 2·6)
2·3 (2·1 to 2·5)
2·2 (1·5 to 3·0)
–32·4 (–35·8 to –29·4)
–33·4 (–38·3 to –28·5)
–31·0 (–37·1 to –21·9)
2·6 (–2·1 to 6·6)
23·1 (18·6 to 27·5)
–25·3 (–29·3 to –20·4)
16·4 (7·4 to 24·9)
6·4 (0·4 to 13·3)
21·6 (12·6 to 27·4)
–2·2 (–4·3 to –0·2)
–15·1 (–31·5 to –5·0)
–51·0 (–64·9 to –30·4)
–12·5 (–13·8 to –11·3)
–4·5 (–9·7 to 0·1)
–7·4 (–9·9 to –4·8)
–1·8 (–6·9 to 2·5)
–32·9 (–37·5 to –28·0)
–8·5 (–14·6 to 2·1)
–21·3 (–30·2 to –13·5)
6·0 (0·0 to 11·1)
0·8 (–0·4 to 2·1)
–10·9 (–12·9 to –8·8)
–59·2 (–64·0 to –50·3)
–9·3 (–13·5 to –5·9)
–43·8 (–48·4 to –38·7)34·0 (22·8 to 46·2)
110·0 (99·8 to 118·1)
25·2 (3·2 to 41·2)
–6·3 (–16·9 to 14·6)
112·0 (106·4 to 117·6)
139·5 (136·5 to 142·6)
153·7 (138·7 to 166·6)
82·3 (62·1 to 100·9)
117·0 (102·1 to 142·3)
55·0 (43·8 to 66·6)
148·6 (134·8 to 161·9)
124·7 (119·3 to 130·7)
126·9 (113·4 to 138·3)
105·7 (100·2 to 111·4)
15·1 (–16·8 to 65·3)
106·0 (68·5 to 131·7)
137·8 (132·0 to 143·9)
196·0 (173·9 to 211·1)
166·4 (151·1 to 183·4)
164·3 (143·6 to 183·8)
87·4 (76·2 to 99·6)
190·7 (179·4 to 201·0)
180·0 (168·0 to 194·7)
63·6 (49·1 to 86·1)
60·5 (48·7 to 72·5)
66·6 (57·7 to 74·2)
2·5 (2·3 to 2·7)
2·5 (1·9 to 3·3)
2·4 (1·8 to 2·7)
1·7 (1·3 to 2·2)
1·1 (1·0 to 1·2)
0·8 (0·8 to 0·9)
1·4 (1·1 to 1·8)
1·6 (1·5 to 1·8)
2·0 (1·5 to 2·7)
2·3 (1·9 to 2·5)
·
·
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tuberculosis, road injuries, stroke, and, to a lesser extent, 
low back pain and ischaemic heart disease. For similar 
reasons as in the previous age group, HIV/AIDS 
DALY rates increased substantially. The increase in the 
residual “other musculoskeletal disorder” category is 
more difficult to interpret, as it is a collection of several 
individual diseases. HIV/AIDS, ischaemic heart disease, 
stroke, and head ache disorders appeared in the top-ten 
rankings for DALYs for both males and females in 2019. 
Three injury causes (road injuries, self-harm, and inter-
personal violence) and cirrhosis ranked prominently 
among males but not females. Among females, gynae-
cological disorders, depressive disorders, other musculo-
skeletal disorders, maternal disorders, and anxiety 
disorders were top ten causes (appendix 2 figures S9, S10).
In 2019, the ten leading causes of DALYs in age groups 
50–74 years and 75 years and older largely overlapped. 
Ischaemic heart disease and stroke were ranked first 
and second, respectively, in both age groups. Chronic 
obstructive pulmonary disease (COPD), diabetes, lung 
cancer, chronic kidney disease, and age-related hearing 
loss appeared in the top ten in both age groups. For ages 
50–74 years, low back pain, cirrhosis, and road injuries 
were the remaining top-ten-ranking causes of DALYs, 
whereas Alzheimer’s disease and other demen tias, lower 
respiratory infections, and falls appeared in the top ten for 
those aged 75 years and older. The most notable changes 
in top ten causes in these two age groups between 
1990 and 2019 were large declines in age-standardised 
DALY rates for ischaemic heart disease, stroke, COPD, 
cirrhosis, and road injuries, but increases in DALY rates 
for diabetes and chronic kidney disease. There was a 
decline in age-standardised lung cancer rates for ages 
50–74 years, but an increase in the oldest age category. The 
ten leading causes for DALYs by sex in both of these older 
age groups largely overlapped in 2019. Among 50–74-year-
olds, breast cancer, other musculoskeletal disorders, and 
depressive disorders appeared in the top ten for females 
only, while road injuries, cirrhosis, and tuberculosis made 
it into the top ten for males. For the oldest age group, falls 
and hypertensive heart disease ranked in the top ten 
among females, but not males; lung cancer and prostate 
cancer ranked among the top ten in males (appendix 2 
figures S9, S10).
National trends
Countries and territories vary widely in their stages of the 
epidemiological transition. With increasing SDI, we 
expect to see a shift in the burden of disease from commu-
nicable, maternal, neonatal, and nutritional diseases 
towards non-communicable causes. We also expect to 
see a shift towards a larger fraction of the burden due to 
YLDs compared with YLLs. These two major trends can 
be summarised by the percentage of all-cause DALYs 
made up of non-communicable disease and injury YLDs. 
Figure 3 shows this proportion across 204 countries and 
territories in 1990 and 2019. In 2019, this measure of the 
epidemiological transition ranged from 8·4% (95% UI 
6·2–10·9) in Chad to 56·9% (48·7–64·3) in Qatar. 
The values in 1990 ranged from 3·5% (2·6–4·7) in Niger 
to 47·5% (37·6–56·0) in Andorra. In 2019, non-commu-
nicable and injury YLDs contributed to more than half of 
all disease burden in 11 countries. All but two countries, 
Ukraine and Lesotho, had higher ratios in 2019 compared 
with 1990.
When comparing the annualised rate of change in age-
standardised DALY rates for all causes except HIV/AIDS, 
natural disasters, and war and conflict between the time 
periods 1990–2010 and 2010–19 for each country and 
territory, the rate, as shown by a simple linear regression 
line, is steeper in the latter time period, suggesting that 
change has accelerated over the last decade in countries 
and territories at the lower end of the SDI range (figure 4). 
Improvements have started to stagnate, or even reverse, 
in countries with higher SDI, as is the case in Dominica, 
the Dominican Republic, Guam, Jamaica, Saint Lucia, 
Saint Vincent and the Grenadines, Ukraine, the USA, and 
Venezuela. Countries with greater than 2% annual reduc-
tions in age-standardised DALY rates over both time 
periods were Ethiopia, Angola, Burundi, Malawi, Sudan, 
Myanmar, Laos, and Bangladesh. Four countries from the 
former Soviet Union—Russia, Belarus, Kazakhstan, and 
Uzbekistan—experienced increases in age-stan dardised 
DALY rates between 1990 and 2010, but recovered in 
the following decade; Russia, Kazakhstan, and Belarus 
experienced an estimated annual decline of 2% or greater 
between 2010 and 2019, and Uzbekistan experienced an 
estimated 1·5% annual decline. Another former Soviet 
Union republic, Ukraine, saw modest decline in the 
1990 to 2010 period, but a worsening trend in the decade 
after.
Cause-specific trends
Two-page cause-specific summaries provide detailed 
results on mortality, prev alence, incidence, YLLs, YLDs, 
and DALYs for a selection of diseases, injuries, and 
impairments in the GBD cause hierarchy. These sum-
maries include 2019 counts, age-standardised rates, and 
rankings; the fraction of DALYs attributed to risk factors; 
patterns over time and age; and the relationship between 
SDI and DALY rates by country or territory. They were 
written to increase the accessibility to and transparency 
of GBD estimates for each cause. Summaries for select 
causes are highlighted in print (pp S2–213); summaries 
for all diseases, injuries, and impairments can be found 
online.
Discussion
Main findings
Global health has steadily improved over the past 
30 years, as measured by changes in age-standardised 
DALY rates. While health has improved, after accounting 
for population growth and ageing, the absolute number 
of DALYs has remained stable. The shift to a much 
For all two-page summaries see 
https://www.thelancet.com/
gbd/summaries
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Figure 3: Proportion of total DALYs contributed by injury and non-communicable disease YLDs, by country or territory, 2019
Proportions were rounded to the nearest whole number. DALY=disability-adjusted life-year. YLD=year lived with disability.
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greater number of DALYs occurring at older ages, despite 
reductions in age-standardised DALY rates, illustrates 
the importance of understanding how ageing shapes 
future health needs. Policy makers should remain aware 
that the number of DALYs represents the burden of 
disease that the world’s health systems must manage.
Although most diseases showed a pattern of stable or 
slowly changing rates of death and disability over the 
study period, there are some notable exceptions. Deaths 
due to drug use disorders have risen sharply over the 
past decade. In 2019, more than half of all global overdose 
deaths occurred in the USA. Liberal prescribing of high-
dose opioids, inadequate provision of opioid substitution 
therapy, and the lacing of street drugs with highly 
potent opioids such as fentanyl are considered major 
contributors to this public health crisis.14–17 By contrast, a 
positive, rapid change in disease rates has taken place in 
Egypt, where close to 80% of the population aged 12 years 
and older has been screened for hepatitis C, and those 
with detectable virus are treated with a low-cost treatment 
regimen.18,19 We estimated that the number of cases of 
chronic hepatitis C has dropped by 65·9% (95% UI 
51·1–79·7) since screening and treatment were initiated 
through regular health services in 2014 and an enhanced 
national screening programme for the whole population 
aged 12 years and older was established in 2019.19 Egypt 
had the highest prevalence of chronic hepatitis C in the 
world, ascribed to iatrogenic infection during treatment 
campaigns for schistosomiasis in the 1960s and 1970s.20–22 
The sharp decline in chronic infections in Egypt is 
expected to be reflected in a large decline in deaths 
from cirrhosis and liver cancer in coming years. Unlike 
hepatitis B vaccination in children, where the effect of 
intervention cannot be expected until several decades 
later, removal of hepatitis C virus in the adult population 
leads to more immediate health impact.
In children younger than 10 years, the decline in 
neonatal disorders was slower than for the major 
infectious diseases, thus increasing neonatal disorders’ 
share of total DALYs. Among injuries in this age group, 
drowning saw the largest decline in DALYs. The position 
of congenital syphilis among the top ten causes of 
DALYs in children is indicative of health system failure. 
With testing and treatment in the second trimester of 
pregnancy, this cause could be eliminated.23 The main 
reasons for failure are limited access to health services, 
the low use of rapid diagnostic tests, the failure of 
antenatal clinics to screen or treat when a woman is 
Figure 4: Annualised rate of change in age-standardised DALY rates for all causes excluding HIV/AIDS, natural disasters, and war and conflict, and SDI by 
country or territory, for 1990–2010 (A) and 2010–19 (B)
A simple linear regression line is shown in each figure for the relationship between annualised rate of change and the average SDI value of each country and territory 
for each time period. AFG=Afghanistan. AGO=Angola. ARE=United Arab Emirates. BDI=Burundi. BGD=Bangladesh. BLR=Belarus. BOL=Bolivia. BTN=Bhutan. 
CHN=China. CIV=Côte d’Ivoire. CMR=Cameroon. COD=Democratic Republic of the Congo. DALY=disability-adjusted life-year. DMA=Dominica. DOM=Dominican 
Republic. ERI=Eritrea. ETH=Ethiopia. GHA=Ghana. GNB=Guinea-Bissau. GNQ=Equatorial Guinea. GTM=Guatemala. GUM=Guam. IND=India. JAM=Jamaica. 
KAZ=Kazakhstan. KHM=Cambodia. KOR=South Korea. KNA=Saint Kitts and Nevis. LAO=Laos. LBR=Liberia. LCA=Saint Lucia. LSO=Lesotho. MDA=Moldova. 
MDV=Maldives. MMR=Myanmar. MOZ=Mozambique. MRT=Mauritania. MWI=Malawi. NER=Niger. NGA=Nigeria. NPL=Nepal. NRU=Nauru. OMN=Oman. PER=Peru. 
RUS=Russia. RWA=Rwanda. SDN=Sudan. SGP=Singapore. SLE=Sierra Leone. SOM=Somalia. SWZ=eSwatini. TGO=Togo. TLS=Timor-Leste. TUR=Turkey. UKR=Ukraine. 
UZB=Uzbekistan. VCT=Saint Vincent and the Grenadines. VEN=Venezuela. YEM=Yemen. ZAF=South Africa. ZWE=Zimbabwe. SDI=Socio-demographic Index.
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tested positive, and the recent global shortage of 
benzathine penicillin, the treatment of choice.24 Despite 
the large health gains among children younger than 
10 years, considerable burdens still remain in sub-
Saharan Africa. Sustaining the global pace of progress 
will become more challenging as an ever-increasing 
proportion of the global birth cohort is born in sub-
Saharan Africa,25 with the highest rates of burden in 
these age groups. It is encouraging, however, that the 
largest decreases in DALY rates globally have occurred in 
sub-Saharan African countries, such as Ethiopia, Angola, 
Rwanda, and Malawi, although there are others that 
have seen much less progress.
Among the top ten causes of DALYs in adolescents 
aged 10–24 years, self-harm had the largest decline 
(28·4% [95% UI 18·9–36·3]) over the study period. The 
prevalence of depressive disorders and other mental 
disorders, which are major underlying causes of self-
harm,26 did not change, sug gesting that the decline in 
self-harm deaths was largely due to other factors such as 
better access to mental health services, urbanisation, and 
a reduction in access to more lethal means of suicide.27–30 
The increase in DALY rates of neonatal disorders in this 
age group is a downside to the large improvements in 
neonatal survival, causing a greater proportion of the 
surviving babies to have long-term neurological and 
sensory deficits.
In the 25–49-year age group, HIV/AIDS was the second 
leading cause of DALYs in 2019 despite a drop since 2005, 
when ART became more widely available.31 To be on 
course to end HIV/AIDS as a public health threat 
by 2030, UNAIDS estimates that a substantial increase in 
global funding would be required, whereas high-income 
countries have reduced their funding.32 The prominent 
position of headache disorders in the DALY rankings in 
the 10–24-year and 25–49-year age groups has received 
little attention in global health policy debates. While 
there is no cure for these disorders, there are effective 
symptomatic and preventive treatments available.33 
Ischaemic heart disease, stroke, and diabetes were not 
among the 25 leading causes in the two younger age 
groups, but emerged as major contributors to burden in 
the 25–49-year age group and, more prominently, in the 
older age groups that follow. These diseases share many 
common risk factors and treatment approaches. The 
burden in high-income countries has been rapidly 
declining since the 1980s, but a more recent downturn in 
this decline over the past 5 years has been noted as an 
important explanation for the slowdown in life expectancy 
gains.34 Low-income and middle-income countries still 
have ample opportunity to make greater use of known 
effective intervention strategies (tobacco control, blood 
pressure-lowering and cholesterol-lowering treatments, 
and emer gency response and treatment for acute events) 
that have been so effective in high-income countries.35 
However, the rising prevalence of diabetes, linked to the 
almost ubiquitous increase in body-mass index globally,36 
is mitigating the pathway to reducing the burden of 
cardiovascular diseases.37,38 In the 25–49-year age group, 
tuberculosis that is not associated with HIV infection 
ranked among the top ten causes in 2019. There are 
similar worries about sustained global funding of 
tuberculosis control as mentioned for HIV/AIDS, let 
alone having the additional resources and research 
development effort that would be required to reach 
WHO’s goals to reduce the 2015 levels of tuberculosis 
deaths and incidence by 90% and 80%, respectively, by 
the year 2030.39–41
The prominent rankings of COPD and lung cancer 
in the 50–74-year and 75-years-and-older age groups 
emphasise the continuing need for tobacco-control 
measures and attention to reducing exposure to indoor 
and outdoor air pollution. Already, low-income and 
middle-income countries account for 62·6% of the 
global burden of COPD and lung cancer, and this share 
is likely to increase sharply over coming decades due to 
ageing populations and less successful tobacco and air 
pollution control. The finding that lung cancer DALY 
rates are declining in the 50–74-year age group but not in 
those aged 75 years and older is probably due to a cohort 
effect; this could be encouraging if it reflects a greater 
response to tobacco control in younger generations that 
will drive further declines in coming years. Chronic 
kidney disease is strongly linked to cardiovascular 
diseases and diabetes, and shares common risks and 
intervention approaches.42 Given its prominent position 
in the top ten rankings of DALYs in older age groups and 
the costs associated with end-stage kidney disease 
treatments, screening and low-cost treatments at earlier 
stages of chronic kidney disease should be more widely 
implemented.43 Cirrhosis ranked seventh among those 
aged 50–74 years in 2019. With low-cost treatments 
available to low-income and middle-income countries, 
there is an opportunity to eradicate hepatitis C as an 
underlying cause—a strategy that Egypt is well on the 
way to achieving in coming years.19 Child hood vac-
cinations for hepatitis B will eventually also reduce 
cirrhosis (and liver cancer) outcomes, but the full effect 
will probably not be apparent for years. Alcohol is the 
third modifiable cause of cirrhosis; there is strong 
evidence that taxation and regulations can reduce alcohol 
use to less harmful levels.44 Age-related hearing loss is a 
top ten cause of DALYs in the two older age groups. 
While some reduction in burden can be achieved by 
control of loud noises during leisure or occupational 
activities, most of the burden cannot be prevented 
through currently known strategies. For a large propor-
tion of the elderly, hearing aids can relieve some of the 
symptoms and associated social isolation. The quality of 
hearing aids has improved over the past decade, but low-
cost appliances are not readily available in low-income 
and middle-income countries.45
Alzheimer’s disease and other dementias, and falls are 
two causes that appear in the top ten ranking of DALYs 
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only for those aged 75 years and older. The ability to 
intervene by prevention or treatment for dementia is still 
limited despite a large research and development effort 
to identify drugs, but efforts continue.46 There is good 
evidence that a range of modifiable risks (tobacco, 
physical inactivity, metabolic risks, and hearing loss) 
contribute to the development of dementia,47,48 but little 
evidence of the effectiveness of interventions addressing 
these risk factors.47,49 Falls in the elderly are common and 
linked to psychotropic and cardiovascular medications,50 
cognitive impairment, depression, and general frailty.51,52 
There is evidence for the effectiveness of multifactorial 
interventions combining education, exercise, and home 
safety modification interventions.53
The trend towards disability as an increasing share of 
overall burden has continued. In 11 countries, more than 
half the burden was from YLDs of NCDs and injuries in 
2019. To some extent, the absence of a discernible trend 
in disability might be an artifact of the poor availability of 
data on severity, and, therefore, an inability to quantify 
the effect of health service interventions that modulate 
severity. The larger issue, however, is that most of the 
focus of global public health has been on life-saving 
interventions directed at the main causes of death.7,54,55 
The large contributors to disability, such as muscu-
loskeletal conditions and mental disorders, are associated 
with few deaths. As disability becomes an increasingly 
large component of disease burden and, as importantly, 
a larger component of health expenditure, a greater 
research development investment is needed to identify 
new, and more effective, intervention strategies.56–58 With 
a rapidly ageing global population, the demands on 
health services to deal with disabling outcomes, which 
increase with age, will require policy makers to anticipate 
these changes. GBD provides key information on the 
changes in types of health services in terms of facilities 
and adequately trained personnel that will be needed.
The finding that health gains in countries at the lower 
end of the SDI scale have, on average, accelerated over the 
past decade compared with the two decades before 
indicates the potential for low-income countries to make 
a real difference by investing in health. Progress, however, 
has been uneven. The more recent downturn in reduc-
tions in DALY rates in countries and territories with 
higher SDI is striking and near universal, although an 
actual reversal into increases of age-standardised DALY 
rates has only happened in a small number of countries 
in the Caribbean and the USA. Plausible drivers of this 
change include obesity, diminishing potential for further 
reductions in smoking, and improvements in coverage of 
treatments for high blood pressure and cholesterol to 
maintain the past declines in cardiovascular mortality.34 
Inequalities in access to preventive and curative services 
by lower socioeconomic groups might be a further 
obstacle to continued improvements in cardiovascular 
mortality.59 The large increase in drug overdose deaths in 
the USA and the increasing number of deaths from 
violence in Latin American countries, in addition to 
the decelerated decline of cardiovascular mortality, are 
driving the patterns in these locations. The mix of 
universal and more geographically specific influences on 
health reinforces the need for regular, detailed reporting 
on population health by underlying cause to help decision 
makers to identify success stories of disease control, as 
well as opportunities to improve and emulate countries 
that are performing well.
Limitations
The major limitation of the GBD analysis of the burden 
of diseases and injuries is the availability of primary data. 
Where data are not available, the results depend on the 
out-of-sample predictive validity of the modelling efforts. 
While improvements to data processing and modelling 
can lead to incremental improvements in the accuracy of 
our estimates, fundamental improvements require more 
and better primary data collection. Even when data are 
available, they might not have been obtained using 
the preferred case definition or measurement method. 
The more explicit identification of the preferred and 
alternative measurement method for each outcome, and 
the bias mapping from alternative to reference method 
undertaken as part of GBD 2019, have led to greater 
stability in data adjustments. These improvements will 
also aid in identifying priorities for data collection and 
in determining preferred case definitions and study 
methods. Moving to use of standard locations for 
estimating fixed effects in the models will aid in cycle-to-
cycle stability of models. Through the use of standard 
locations, the addition of more subnational units in a 
given GBD cycle should not shift the regression model 
predictions as much as they previously would have. 
Nevertheless, collinearity between covariates in some of 
these models might contribute to some instability in 
fixed effects between cycles. Future work on ensemble 
models might help to solve the collinearity problem. Of 
note, because the cause of death models developed using 
CODEm are an ensemble of all high-performing possible 
models, they avoid the instability due to collinearity. 
Although our statistical modelling is designed to capture 
uncertainty from stochastic variation in input data, age 
and sex splitting of data, corrections for alternative case 
definitions or uninformative cause of death codes, other 
data manipulations, and model choice, it remains a 
challenge to fully represent the UIs around estimates, 
particularly in locations with sparse or absent data. This 
will remain a major focus of GBD by tapping into existing 
knowledge in other estimation fields as well as our own 
development of methods.
The shift to adjusting dementia deaths to reflect 
only those with end-stage disease is conceptually more 
appealing than the past crude adjustment for the large 
variation in coding practices. We will, however, need to 
replicate the methods of determining the share of excess 
mortality in people with dementia who are in the last 
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stages of the disease and for whom an assignment of 
dementia as the underlying cause of death is therefore 
justified. A greater focus in future rounds of GBD will 
need to be directed to identifying data of treatment effects 
on severity distributions of the large contributors to 
YLDs, such as mental, neurological, and musculoskeletal 
disorders, for which we currently do not distinguish 
geographical variation in severity. This is of particular 
importance as these conditions represent an increasing 
share of total burden. Our effort to improve the consis-
tency between mortality rates, prevalence, and incidence 
for selected conditions by providing more explicit 
guidance on excess mortality rates in DisMod-MR has 
revealed that more attention will be required in future 
rounds of GBD. After imposing a pattern of excess 
mortality that follows an expected pattern of lower rates 
in countries with better health systems, the models might 
predict prevalence or incidence estimates that are far 
removed from observed data. The challenge is then to 
identify whether the inconsistency is due to error in the 
cause of death estimates, the non-fatal data sources, or a 
combination of the two. In addition to these general 
limitations, there are many limitations for each specific 
modelling exercise reported in this study. Appendix 1 
(sections 3.4 and 4.12) provides more insight into some of 
these issues.
Future directions
Several method improvements signalled in previous 
GBD publications have not yet been implemented but 
remain a priority. For instance, DisMod-AT, a new version 
of our main non-fatal modelling tool that simultaneously 
solves for patterns over age and time, is still undergoing 
testing before it can be implemented in GBD. Methods to 
make dependent comorbidity corrections computationally 
feasible, and imposing greater variation in severity 
distributions based on access to and quality of health 
care, are also still under development. More generally, 
imposing GBD principles and methods to the estimation 
of access to health interventions and the effectiveness 
thereof, and being able to link those estimates with our 
future health scenario platform25 is a direction we are 
keen to take. Developing this comprehensively is a large 
endeavour that will take many years to complete. As this 
would greatly add value to the policy relevance of GBD, 
we will also aim to develop less comprehensive methods 
that will nevertheless allow us to respond to policy makers 
seeking information on major policy decisions in a more 
timely fashion.
Conclusion
Taking into account population growth and shifts in age 
structure, health continues to improve at the global level. 
The absolute burden of disease and its associated impact 
on health systems, however, remain resolutely constant. 
Some diseases, such as diabetes, are increasing in 
burden, and more general all-cause DALY stagnation in 
some high SDI countries points out that further gains 
are not inevitable. Close monitoring of health trends and 
careful policy evaluation of the options to counteract 
adverse trends is required. Leading causes of DALYs, as 
well as solutions, differ substantially across age groups, 
highlighting the need to formulate policy for different 
phases of the life course.
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